Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
BCG vaccination reduces the mortality of Mycobacterium tuberculosis–infected type 2 diabetes mellitus mice
Rajesh Kumar Radhakrishnan, Ramya Sivangala Thandi, Deepak Tripathi, Padmaja Paidipally, Madeline Kay McAllister, Sachin Mulik, Buka Samten, Ramakrishna Vankayalapati
Rajesh Kumar Radhakrishnan, Ramya Sivangala Thandi, Deepak Tripathi, Padmaja Paidipally, Madeline Kay McAllister, Sachin Mulik, Buka Samten, Ramakrishna Vankayalapati
View: Text | PDF
Research Article Immunology Infectious disease

BCG vaccination reduces the mortality of Mycobacterium tuberculosis–infected type 2 diabetes mellitus mice

  • Text
  • PDF
Abstract

Diabetes is a significant risk factor for the development of active tuberculosis. In this study, we used a mouse model of type 2 diabetes mellitus (T2DM) to determine the effect of prior Bacillus Calmette-Guérin (BCG) vaccination on immune responses to Mycobacterium tuberculosis (Mtb) infection. We found that, at 6–7 months after Mtb infection, 90% of the Mtb-infected T2DM mice died, whereas only 50% of BCG-vaccinated T2DM-Mtb–infected mice died. Moreover, 40% of the PBS-treated uninfected T2DM mice and 30% of the uninfected BCG-vaccinated T2DM mice died, whereas all uninfected and infected nondiabetic mice survived. BCG vaccination was less effective in reducing the lung bacterial burden of Mtb-infected T2DM mice compared with Mtb-infected nondiabetic mice. BCG vaccination significantly reduced lung inflammation in Mtb-infected T2DM mice compared with that of unvaccinated T2DM mice infected with Mtb. Furthermore, reduced mortality of BCG-vaccinated Mtb-infected T2DM mice is associated with expansion of IL-13–producing CXCR3+ Tregs in the lungs of Mtb-infected T2DM mice. Recombinant IL-13 and Tregs from BCG-vaccinated Mtb-infected T2DM mice converted proinflammatory M1 macrophages to antiinflammatory M2 macrophages. Our findings suggest a potentially novel role for BCG in preventing excess inflammation and mortality in T2DM mice infected with Mtb.

Authors

Rajesh Kumar Radhakrishnan, Ramya Sivangala Thandi, Deepak Tripathi, Padmaja Paidipally, Madeline Kay McAllister, Sachin Mulik, Buka Samten, Ramakrishna Vankayalapati

×

Figure 7

IL-13 produced by Tregs is involved in the expansion of antiinflammatory M2 macrophages.

Options: View larger image (or click on image) Download as PowerPoint
IL-13 produced by Tregs is involved in the expansion of antiinflammatory...
(A) At four months p.i., the formalin fixed and paraffin embedded lungs sections from Mtb-infected BCG-vaccinated and BCG-vaccinated T2DM were analyzed by confocal microscopy for Foxp3+IL13+ cells. Foxp3 (red), IL-13 (green), and DAPI (blue) expression is shown. Scale bar: 20 μm. BCG-vaccinated T2DM mouse splenocytes were isolated and cultured at 1 × 106 cells/well in RPMI-1640 containing penicillin (Invitrogen) and 10% heat-inactivated FCS, with or without γ-irradiated Mtb H37Rv (10 µg/mL) at 37°C and 5% CO2. In some wells, Treg-depleted splenocytes were stimulated with γ-irradiated Mtb (10 µg/mL). After 72 hours, the cells were collected and phenotypically characterized for M1/M2 macrophages, and the supernatants were used to measure levels of the cytokine IL-13. (B) Mean fluorescence intensity (MFI) values showing the CD45+F4/80+iNos+ and CD45+F4/80+Arg1+ cells, and IL-13 levels in culture supernatants, were measured by ELISA. (C) BCG-vaccinated nondiabetic and BCG-vaccinated T2DM mouse splenocytes were stimulated with γ-irradiated Mtb H37Rv (10 µg/mL) and treated with anti–IL-13R (10 µg/mL) for 72 hours. After 72 hours, flow cytometry was performed to determine the M2 macrophage phenotype (CD45+F4/80+Arg1+ cells). (D) MFI values and histogram plot showing IL-13R expression gated on CD45+F4/80+Arg1+ cells. (E) Macrophages isolated from BCG-vaccinated mice were cocultured with autologous Tregs or Tregs isolated from BCG-vaccinated T2DM mice and stimulated with γ-irradiated Mtb (10 µg/mL). After 72-hour incubation, the macrophages were analyzed for M1 and M2 phenotype by flow cytometry. MFI values showing the CD45+F4/80+iNos+ cells and CD45+F4/80+Arg1+ cells. (F) For neutralization studies, BCG-vaccinated T2DM mouse macrophages were stimulated with γ-irradiated Mtb (10 µg/mL) with or without autologous Tregs, and in some wells, IgG control or anti–IL-13R (10 µg/mL) antibodies were added. After 72 hours of incubation, the M1 and M2 phenotypes of cultured macrophages were determined by flow cytometry, and TNF-α and IL-6 levels were measured by ELISA in the culture supernatants. rIL-13 (10 ng/mL) was added to the macrophages from BCG-vaccinated T2DM mice and stimulated with γ-irradiated Mtb (10 µg/mL). (G) After 72 hours of incubation, the M1 and M2 phenotypes of cultured macrophages were determined by flow cytometry, and MFI values for CD45+F4/80+iNos+ cells and CD45+F4/80+Arg1+ cells are shown. Experiments were performed 2 times, and each time, 2–3 mice per group were used. The data are shown as mean ± SDs of n = 5 mice per group. The statistical analysis was performed by 1-way ANOVA, followed by Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, and ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts